항체 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Antibody Therapeutics Market size is expected to reach USD 1059.60 Billion in 2034 from USD 316.47 Billion (2025) growing at a CAGR of 14.37% during 2026-2034.

The Global Antibody Therapeutics Market is witnessing substantial growth due to increasing demand for targeted treatments. Monoclonal antibodies are widely used in oncology, autoimmune diseases, and infectious diseases. Rising prevalence of chronic conditions and advancements in biotechnology are supporting market expansion.

Key growth drivers include expansion of biologics pipelines and increasing R&D investments. Pharmaceutical companies are developing next-generation antibodies with improved specificity and reduced side effects. Growing healthcare expenditure and favorable reimbursement policies are further boosting demand. Additionally, advancements in antibody engineering technologies are enhancing therapeutic efficacy.

Looking ahead, the market is expected to benefit from biosimilar development and novel antibody formats. Emerging markets improving access to biologic therapies will create growth opportunities. Companies are focusing on innovative delivery methods and combination therapies. As precision medicine continues to evolve, the Global Antibody Therapeutics Market is projected to grow steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Format

• Monoclonal Antibody
• Polyclonal Antibody Therapy
• Bispecific Antibody
• Antibody Fragment
• Other

By Disease Areas

• Autoimmune & Inflammatory Diseases
• Oncology
• Hematology
• Infectious Diseases
• Osteology
• Immunology
• Neurology
• Other

By Route Of Administration

• Intravenous
• Subcutaneous

By Source

• Human
• Humanized
• Chimeric
• Other

By End User

• Hospitals
• Long-Term Care Facilities
• Other

COMPANIES PROFILED

• F HoffmannLa Roche Ltd Switzerland, AbbVie Inc US, Johnson Johnson US, Merck KGaA Germany, BristolMyers Squibb US, AstraZeneca UK, Sanofi France, Regeneron Pharmaceuticals, Inc US, Novartis AG Switzerland, Amgen, Inc US, Biogen Inc US
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY FORMAT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Format
• 4.2. Monoclonal Antibody Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Polyclonal Antibody Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Bispecific Antibody Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antibody Fragment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY DISEASE AREAS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Areas
• 5.2. Autoimmune & Inflammatory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Osteology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY SOURCE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Source
• 7.2. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Long-Term Care Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Format
  • 9.2.2 By Disease Areas
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Source
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Format
  • 9.3.2 By Disease Areas
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Source
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Format
  • 9.4.2 By Disease Areas
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Source
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Format
  • 9.5.2 By Disease Areas
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Source
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Format
  • 9.6.2 By Disease Areas
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Source
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ANTIBODY THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 F. Hoffmann-La Roche Ltd. (Switzerland)
  • 11.2.2 AbbVie Inc. (US)
  • 11.2.3 Johnson & Johnson (US)
  • 11.2.4 Merck KGaA (Germany)
  • 11.2.5 Bristol-Myers Squibb (US)
  • 11.2.6 AstraZeneca (UK)
  • 11.2.7 Sanofi (France)
  • 11.2.8 Regeneron Pharmaceuticals, Inc. (US)
  • 11.2.9 Novartis AG (Switzerland)
  • 11.2.10 Amgen, Inc. (US)
  • 11.2.11 Biogen Inc. (US)